Compare ATON & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATON | PHGE |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | British Virgin Islands | United States |
| Employees | 4 | 57 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | ATON | PHGE |
|---|---|---|
| Price | $0.30 | $4.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 323.3K | 65.7K |
| Earning Date | 02-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.25 |
| 52 Week High | $13.80 | $8.50 |
| Indicator | ATON | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 42.86 |
| Support Level | N/A | $4.00 |
| Resistance Level | $3.30 | $5.99 |
| Average True Range (ATR) | 0.03 | 0.76 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 10.26 | 4.50 |
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).